ClinicalTrials.gg
RecruitingNCT05643872Updated Dec 9, 2022

A Study Evaluating the Safety and Pharmacokinetics of QTORIN Rapamycin 3.9% Anhydrous Gel in the Treatment of Adults With Pachyonychia Congenita

A Phase 3 interventional study of PTX-022 in Pachyonychia Congenita, sponsored by Palvella Therapeutics, Inc.. Recruiting at 1 site in United States. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2022-12-09.

Sponsored by Palvella Therapeutics, Inc. · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Oct 2023, 3 years 1 month ago, but the record still lists the study as recruiting.
  • Started Nov 2022; still recruiting 4 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
45
Allocation
Not applicable
Ages
16 Years and older
Sex
All
01

Study summary

PALV-08 is a multicenter, open-label treatment (OLT) study enrolling adults with Pachyonychia Congenita (PC) with genotyped keratin mutations KRT6A, KRT6B, KRT6C or KRT16 who were previously enrolled in the PALV-05 (VAPAUS) trial.

The purpose of this OLT study is to investigate the safety of long term exposure and pharmacokinetics (PK) of QTORIN rapamycin 3.9% anhydrous gel or "PTX-022".

02

Conditions studied

  • Pachyonychia Congenita
03

In context

Lead sponsor

Palvella Therapeutics, Inc. is the lead sponsor of 9 studies on the registry; 2 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 1 (20%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Completed the PALV-05 (VAPAUS) study
  • Agree to use

Key Exclusion Criteria:

  • Females who are pregnant or breastfeeding
  • Concomitant use of sirolimus or any sirolimus-containing medications (systemic or topical)
  • Any significant concurrent condition that could adversely affect participation and/or the assessment of the safety and efficacy in the study
  • Prior or planned treatment, including surgery or other medically necessary intervention deemed by the investigator that could adversely affect participation and/or the assessment of the safety and efficacy in the study
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
45 participants (estimated)

Study arms

  • Experimental
    PTX-022

    Drug: PTX-022

Interventions

  • QTORIN rapamycin 3.9% anhydrous gel

06

What researchers measure

Primary outcomes

  1. Treatment emergent adverse events

    Time frame: 6 months

Secondary outcomes

  1. Pharmacokinetic parameters

    AUC area under the sirolimus blood concentration-time profile

    Time frame: Prior to dose, 12 hours and 24 hours

07

Study locations

1 of 1 sites recruiting
  • Minnesota Clinical Study Center
    New Brighton, Minnesota 55112, United States
    Recruiting
    • Study Coordinator · Contact763-502-2929
    • Steven E Kempers, MD, FAAD · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2022 (actual). Primary completion is estimated for Oct 2023, 11 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 8, 2022
First posted
Dec 9, 2022
StartActual
Nov 15, 2022
Primary completionEst.
Oct 2023
CompletionEst.
Nov 2023
Last update
Dec 9, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 9, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05643872
Lead sponsor
Palvella Therapeutics, Inc.
Responsible party
Sponsor
First posted
Dec 9, 2022
Start date
Nov 15, 2022
Primary completion
Oct 2023 (estimated)
Completion
Nov 2023 (estimated)
Last update
Dec 9, 2022

Study contacts

Emily Cook
Contact
emily.cook@palvellatx.com
267-738-6366

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sirolimus Topical Gel PTX-022

Start the discussion